Pharmaceutical compositions with resistance to soluble CEA

US9695250B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Ralf Lutterbüse · Munich, DE
• Petra Fluhr · Munich, DE
• Evelyne Schaller · Munich, DE
• Doris Rau · Munich, DE
• Susanne Mangold · Munich, DE
• Peter Kufer · Munich, DE
• Alexander Murr · Birkenfeld, DE
• Tobias Raum · Munich, DE
• Monika Wissinger · Munich, DE

Key dates

• Filing date: Jan 14, 2013
• Grant date: Jul 4, 2017
• Expiry date: Aug 17, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.